Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease

Xie, Fengjiao; Xiong, Qin; Li, Yilin; Yao, Chengjiao; Wu, Ruike; Wang, Qiuxiang; Luo, Lihong; Liu, Hongling; Feng, Peimin

doi:https://doi.org/10.1155/2022/6275136

Evidence-Based Complementary and Alternative Medicine

On this page

Abstract Introduction Conclusions Conflicts of Interest Authors’ Contributions Acknowledgments References Copyright Related Articles

Review Article | Open Access

Volume 2022 | Article ID 6275136 | https://doi.org/10.1155/2022/6275136

Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease

Fengjiao Xie,^1,2Qin Xiong,¹Yilin Li,¹Chengjiao Yao,^1,3Ruike Wu,^1,2Qiuxiang Wang,¹Lihong Luo,^1,2Hongling Liu,^1,2and Peimin Feng²

Academic Editor: Ivan Luzardo-Ocampo

Received30 Mar 2022

Accepted20 Aug 2022

Published15 Sept 2022

Abstract

Inflammatory bowel disease (IBD), also known as chronic nonspecific inflammatory disease of the colon and rectum, is primarily characterized by mucopurulent bloody stools, diarrhea, abdominal pain, and tenesmus. Its cause is uncertain. IBD patients frequently experience a high rate of recurrence, a protracted treatment course, and a high risk of carcinogenesis. Additionally, the difficulty of treatment is significantly increased by these illness characteristics. Currently, the normal treatment for this illness can lessen symptoms to some amount and even meet clinical treatment requirements, but due to serious side effects, unfavorable reactions, and high costs, we need to develop better complementary and alternative medicines. A number of studies have found that the imbalance of T helper cell 17 (Th17)/regulatory T cells (Treg) contributes significantly to the occurrence and progression of IBD and that Th17/Treg balance restoration is frequently useful in the management of IBD. As a result, regulating the Th17/Treg balance has also emerged as a novel approach to treating IBD. Traditional Chinese medicine (TCM) has gained popularity in recent years due to its advantages of low side effects, a variety of targets, and multiple regulatory mechanisms. A number of studies have shown that TCM can successfully intervene in the Th17/Treg imbalance and restore it, and research on the prevention and treatment of IBD by TCM by restoring Th17/Treg has also shown promising results. The characteristics of the Th17/Treg balance and its role in the pathogenesis of IBD, as well as the role of TCM in regulating the Th17/Treg imbalance, are analyzed. The research results are expected to provide a theoretical basis for the clinical treatment and pathology mechanism research of IBD.

1. Introduction

Crohn’s disease (CD) and ulcerative colitis (UC) are both chronic nonspecific inflammatory diseases that affect the intestines. Diarrhea, abdominal pain, bloody stools, and weight loss are the most typical clinical symptoms [1, 2]. The disease also has a number of extraintestinal symptoms, and the lesions primarily affect the joints, eyes, and skin [3]. Although the pathophysiology of Inflammatory bowel disease (IBD) is not fully understood, it is believed to be a result of complex interactions involving environmental changes, immunological dysregulation, intestinal dysbiosis, and other factors [1]. IBD is becoming more common and prevalent everywhere. It can happen at any age, and IBD patients are severely affected by the financial load [4]. According to a study in the United States, IBD patients accumulate up to $541 million in additional self-pay in treatment each year. Similarly, in a survey of the economic burden of gastrointestinal disease in the United States, IBD was ranked as the fifth most costly gastrointestinal disease in terms of annual healthcare expenditures. The financial and psychological stress on IBD patients’ families is significantly increased by these high medical costs. In conclusion, the incidence of IBD is random, relapsed, and refractory and has a high incidence, high cost of treatment, and many complications making it a global public health problem [2]. IBD is a worldwide illness that has an impact on the health of millions of people. There has been a vigorous hunt for remedies for this illness in recent decades. 5-Aminosalicylates, steroids, immunosuppressive medications, and biological agents make up the majority of the pharmaceuticals used in modern medicine to treat IBD. Surgical treatment is required for some refractory cases or cases with carcinogenesis [5]. The side effects, bad responses, and high expense of various treatment methods all push us to look for further complementary and alternative therapies, even though they can somewhat ameliorate the disease and even meet the standard of clinical treatment. Numerous experimental findings indicate that the imbalance in the T helper cell 17 (Th17)/regulatory T cells (Treg) ratio in IBD patients is a significant contributor to the etiology and also has an impact on the degree of disease activity and inflammation [6]. As a result, restoring Th17/Treg equilibrium by regulation has become a cutting-edge method of treating IBD. Currently, numerous researches have established that TCM regulates the Th17/Treg balance. The effects have also been utilized for IBD, and a number of studies have been conducted with positive outcomes. TCM can be utilized as an alternative and additional treatment option for IBD treatment since it has fewer side effects, multiple targets, multiple techniques, and inexpensive rates. This paper reviews the mechanisms of recent TCM studies on IBD Th17/Treg balance, which helps to support TCM as an alternative and complementary treatment for IBD and also provides more new ideas and references for the treatment of IBD.

2. Role of Th17/Treg cells

Treg and Th17 cells are both descended from CD4+ T cells. When naïve CD4+ T cells are stimulated, they can multiply, develop into other cell types, and secrete various cytokines to carry out their unique roles. In terms of action effects and developmental pathways, there is a strong link between the two, as well as significant plasticity [7, 8]. Treg cells suppress too aggressive immune responses, although Th17 cells among them can trigger inflammation and modulate immunological responses [9]. The function of Th17/Treg balance in a number of autoimmune illnesses has drawn considerable attention since studies have shown that the equilibrium created between these two is necessary for maintaining immunological homeostasis. Studies have confirmed that the balance established between these two is essential for maintaining immune homeostasis, so the role of Th17/Treg balance has received great attention in a variety of autoimmune diseases [10].

2.1. Source and Mechanism of Th17 Cells

Th17 cells, one of the CD4+ T cells, are crucial in autoimmune disorders [11]. Their differentiation essentially consists of three stages: Th17 cells differentiation, Th17 cells differentiation state expansion, and stable Th17 cells maturation [6]. When T cell antigen receptor/costimulatory signals, interleukin- (IL-) 6, and transforming growth factor-beta (TGF-β) stimulation are present, signaling and activator of transcription protein 3 (STAT3) is activated. Following activation, STAT3 further induces the expression of the transcription factor RAR-associated retinoic acid-related orphan receptor gamma t (RORγt), which in turn activates the transcription of IL-17 and IL-22. Second, through STAT3, IL-6 stimulates the production of IL-21, which has a favorable autocrine effect and accelerates the development of Th17 cells. Finally, IL-23R is expressed upon induction of IL-21 and renders IL-23 responsive, a cytokine that maintains the homeostasis of Th17 cell differentiation and is responsible for the stabilization of Th17 cells at later stages [12]. Th17 cells can secrete many key effector cytokines. Among them, IL-17 is one of the most important cytokines secreted by Th17 cells, which can induce the occurrence of inflammation and aggravate the damage of tissues [13]. There are six different isoforms of IL-17, but IL-17A plays a particularly important role since it can be employed by a variety of cells to stimulate the release of chemokines and cytokines [14]. Additionally, during the development of Th17 cells, the promoter region of IL-17A coordinates transcription by binding to RORγt [13]. Moreover, Th17 cells release cytokines, including IL-21 and IL-22, promote the release of proinflammatory molecules, and take involvement in the pathophysiology of autoimmune and metabolic illnesses in addition to enhancing protection against bacterial and fungal infections [10].

2.2. Treg Cells Source and Mechanism

Treg cells are one of the negative immunoregulatory effects of CD4+ T cells and are essential for the maintenance of immune tolerance and balance [6]. Numerous factors also affect their differentiation, and in the absence of proinflammatory cytokines, TGF-β induces CD4+ T cells to differentiate into Treg cells. Through the self-antigen-major histocompatibility complex on thymic antigen-presenting cells, tTreg cells are produced by receiving rather intense T cell antigen receptor stimulation. By undergoing antigenic stimulation under the effect of TGF-β and IL-2 in the periphery, naïve CD4+ T cells are transformed into pTreg cells. Forkhead-like protein 3 (Foxp3), CD4, CD25, and Foxp3 are all markers for T cells, whereas Foxp3 keeps its unique characteristics and functional roles [9]. To decrease naïve T cell activation and avoid the overactivity of effector T cells, Treg cells can produce the cytokines IL-10 and TGF-β, which inhibit the activity of a range of immune cells and, ultimately, the immune response [10]. Additionally, by directly contacting the surface of Th cells and secreting the cytokines IL-10 and TGF-β, Treg cells can suppress other Th isoforms such as Th1, Th2, and Th17 [15]. As a regulator of the immune system, Treg cells can maintain homeostasis and prevent the development of autoimmune diseases.

3. Mechanism of Th17/Treg Cells Balance in IBD

The pathogenicity of the Th17/Treg imbalance has also attracted attention and has been supported by several studies in recent years, as more studies have established that abnormalities of the intestinal mucosal immune system are a crucial element in the incidence and development of IBD [6, 14]. Th17 cells have a different distribution in the intestinal mucosa of UC and CD patients, mainly in the lamina propria of the former and the lower layer and muscle layer of the latter [15]. Th17 cells mainly exert proinflammatory and excessive immune activation roles in the pathogenesis of IBD. Th17 cells furthermore possess some protective qualities. To stop bacterial infection, lessen intestinal inflammation, repair tissue damage, and maintain the integrity of the intestinal barrier, their secreted IL-22 stimulates intestinal epithelial cell proliferation, improves goblet cell function and mucus production, and encourages the production of nucleotide-binding oligomerization domain-containing protein 2 [16]. However, this protective effect is significantly weaker in IBD patients compared with the proinflammatory effect [6]. Th17 cells have many roles in the development of IBD, and they can release the cytokines IL-17, IL-22, and IL-23 that draw neutrophils into the inflammatory process and exacerbate it. In a study, it was discovered that individuals with active IBD had considerably higher levels of Th17 cells, IL-17, and IL-21 expression, which was consistent with disease activity and mucosal injury [17]. In addition, intestinal fibrosis is a common finding in patients with IBD, which can lead to progressive tissue deformation, loss of function, and stenosis of the intestine. IL-17, on the other hand, also plays a great role in it. A recent study showed that anti-IL-17 antibody treatment significantly reduced colorectal fibrosis in colitic mice by downregulating the expression of collagen 3 and several profibrotic cytokines [18]. IL-23 is also an important cytokine, and a study assessing IL-23 expression in human IBD showed that IL-23 production by lamina propria macrophages was increased in CD patients. Recent research has revealed that IL-23 plays a critical role in the modulation of tissue inflammation in IBD and colitis-associated colon cancer [19, 20]. In addition to the Th17 cells acting on IBD through cytokines, there are other influencing factors. Endogenous gut microbiota is involved in Th17 differentiation when the gut microbiota is stable. Studies have confirmed that the intestinal microbiota promotes Th17 cells expansion in areas of intestinal inflammation in mice with experimental colitis with high infiltration of Th17 cells. A study found that E. coli/IL-35-treated mice showed fewer CD4+ IL-17A+ Th17 cells and that disease activity index (DAI), intestinal shortening, and histopathological changes were significantly reduced [21, 22]. In another study by Huang and colleagues, it was found that the supernatant of F. prowazekii improved and prevented colitis in mice by inhibiting Th17 differentiation and IL-17A secretion in plasma and colonic mucosal tissues, downregulating IL-6, and upregulating IL-4 [23]. Treg cells are potent T cells, in contrast to Th17 cells. Peripheral blood and colon mucosa of IBD patients contained fewer Treg cells, suggesting that a lack of Treg cells plays a role in the pathogenesis of IBD [15]. According to the study, IL-10 and TGF-β control Treg cells and the substances they produce, which prevent the intestinal inflammatory cascade from occurring. Additionally, essential routes for IBD recovery include the encouragement of tissue repair, cytolysis of effector cells, metabolic degradation, and inhibitory cytokine secretion [17, 24]. Inflammation of the midgut mucosa in IBD is important in maintaining and promoting the development of colorectal cancer, and Treg cells can effectively prevent and delay inflammation-mediated tumor growth by exerting antitumor activity [25]. In conclusion, Treg cells not only control intestinal inflammation but also suppress the development of autoimmunity.

The preservation of the mucosal immune system’s proper functioning depends on the balance of immune cells in the intestinal mucosa and luminal contents. Th17 and Treg cells normally compete with one another to prevent the other from proliferating and maintain equilibrium. They also play a significant role in controlling T cell-mediated immune responses and reducing intestinal inflammation, and their dysregulation is likely to contribute to the pathogenesis of IBD [26–28]. The proinflammatory effect of Th17 cells causes a serious immune and inflammatory response that outweighs the immune tolerance and protection of Treg cells, which accelerates the progression of IBD. In the IBD state, a number of pathogens penetrate the intestinal epithelial barrier, activate antigen-presenting cells, and induce them to secrete inflammatory cytokines [29]. Numerous studies have also further corroborated that affecting the Th17/Treg balance can lead to the development of IBD. IBD is an independent risk factor for colorectal cancer development [30]. Upregulation of genes associated with Th17/Treg (IL-10, IL-23, and transcription factor Foxp3) was demonstrated to be critical for colorectal cancer development in Velikova’s study [25]. In a number of inflammatory illnesses, the balance of Th17 and Treg cells controls the host immune response. This equilibrium is also intimately tied to intestinal microecology. According to a study, intestinal bile acid metabolites control the balance and operation of Th17 and Treg cells. The intrinsic mechanism is that 3-oxoLCA inhibits Th17 cells differentiation by directly binding to its key transcription factor RORγt and that isoalloLCA enhances Treg differentiation by producing mitochondrial reactive oxygen species, resulting in increased Foxp3 expression [31]. The immunological balance of the IBD colonic mucosa is significantly influenced by Th subsets, particularly Th17 cells and Treg cells. According to an investigation, miR-155 is overexpressed in the colonic mucosa of people with IBD, and miR-155 inhibitors can boost Treg cells and decrease Th17 cells, suggesting that miR-155 relieves colitis by balancing the Th17/Treg ratio. Consequently, the development of IBD therapeutics depends significantly on the balance between Th17 and Treg cells [32]. In summary, the mechanism of Th17/Treg cells balance in IBD does deserve our research attention.

4. Chinese Medicine Treatment Strategy of Balancing Regulation to Prevent and Treat IBD

Due to its traits of having many targets, multiple approaches, high safety, and a low price, TCM provides distinct advantages in the treatment of IBD. With the advancement of contemporary therapy, studies have confirmed that TCM monomers, as well as active ingredients, TCM compounds, and TCM preparations, have a regulatory effect on Th17/Treg balance in IBD. Its mechanism of action has also been presented in the form of pictures (Figure 1). It can be used as an alternative treatment for IBD and has reference value.

Figure 1

Mechanism of action of the monomers and compound formulations of traditional Chinese medicine. Under normal conditions, the intestine does not produce IL-6 due to the lack of pathogen stimulation from antigen-presenting cells, and naïve CD4+ T cells mainly differentiate into Treg cells under TGF-β to prevent the occurrence of autoimmune disease. When pathogens invade, antigen-presenting cells can secrete IL-6, and IL-6 acts together with TGF-β to induce the differentiation of naïve CD4+ T cells to Th17 cells and to inhibit the induction effect of TGF-β on Treg, with an enhanced immune response, contributing to the elimination of pathogens. When the inflammatory effect of Th17 cells exceeds the tolerance effect of Treg cells, the excess cytokines (IL-17, IL-21, IL-22, etc.) act on intestinal epithelial cells, macrophages, and colon myofibroblasts, induce proinflammatory chemokines and other proinflammatory mediators, mediate the early mobilization of granulocytes, and participate in the early inflammatory mediator response, significantly greater than the immune protective effect of cytokines secreted by Treg cells (TGF-β, IL-10, etc.); the body is prone to induce IBD. In this paper, the TCM monomer, extract, and compound (such as Abelmoschus manihot, Daphnetin, epigallocatechin-3-gallate, Baitouweng Decoction, and compound sophorae decoction) are exactly the different stages of the differentiation and regulation of Th17 cells and Treg cells, thus inhibiting the differentiation and production of Th17 cells, reducing the number of associated damage factors that it has secreted, reducing the inhibition of Treg cells differentiation and promoting its production, increasing the number of associated protective factors it secreted, further resulting in restoration of the intestinal immune balance, achieving therapeutic purposes.Abbreviations. AhR: aryl hydrocarbon receptor; AMPK: adenosine 5′-monophosphate- (AMP-) activated protein kinase; ACC1: acetyl-CoA carboxylase 1; CYP1A1: cytochromeP4501A1; CREB: cAMP-response element binding protein; DC: dendritic cells; DNMT-1: DNA methyltransferase-1; Foxp3: forkhead-like protein 3; GPR41: G-protein receptor 41; HIF-1α: hypoxia-inducible factor 1-alpha; IL: interleukin; miR-302: microRNA-302; MAPK: mitogen-activated protein kinase; NF-κB: nuclear factor kappa-B; PPARγ: peroxisome proliferator-activated receptor γ; PHD2: prolyl hydroxylase 2; RORγt: receptor-associated orphan receptor γt; RORC: receptor-associated orphan receptor; STAT3: transcription protein 3; STAT3: transcription protein 3; TGF: transforming growth factor; TLR4: toll-like receptor 4.

4.1. Chinese Herbal Monomers and Their Extracts Prevent and Treat IBD by Regulating Th17/Treg Balance

Studies on the pathogenesis of IBD show that Th17/Treg imbalance is critical, and on this basis, there are also many studies on the treatment of IBD by TCM and its extracts by regulating Th17/Treg imbalance in the body. Paeoniflorin (PF) is a monoterpene glycoside component extracted from the roots of Paeonia lactiflora Pall. It has analgesic, immunomodulatory, and antitumor pharmacological effects [33–35]. A study found that PF can reduce histological scores and alleviate the disease by regulating the Th17/Treg balance mediated by dendritic cells [36]. In addition, PF can also significantly downregulate IL-17 and increase IL-10 levels in experimental colitis models, indicating that PF has the property of reducing inflammatory infiltration [37]. The lipophilic polyphenol curcumin, which is produced from the Curcuma longa root, has its own anti-inflammatory and anti-infective properties [38, 39]. A study showed that curcumin increased the level of cytokine IL-10 by inhibiting the IL-23/Th17 pathway, thereby restoring the balance of Treg/Th17 while reducing the concentration of proinflammatory cytokines. This further reduced the inflammatory response, reducing intestinal endothelial cell swelling, increasing intestinal mucosal permeability, and achieving a therapeutic effect in reducing intestinal inflammation as a whole [40]. 6-Gingerol is an extract of the rhizome of Zingiber officinale Roscoe, which has a number of pharmacological effects, for instance, antioxidation, antitumor, and enhancing immunity [41, 42]. According to a study, 6-gingerol significantly reduced intestinal damage and pathological inflammatory cell infiltration by inhibiting the upregulation of the transcription factor RORγt and the downregulation of the Treg transcription factor Foxp3 in Th17 cells. It also inhibited the increase and decrease in the number of Th17 cells and Treg cells, restoring the balance between the two cell types. Additionally, excessive IL-6 expression leads to an imbalance in the development and functionality of Th17 and Treg cells. 6-Gingerol works by inhibiting IL-6 expression and secretion to maintain the proper ratio of Th17 to Treg cells [43, 44]. An active ingredient derived from Tripterygium wilfordii Hook F., Tripterygium wilfordii polyglycoside, possesses antitumor, immunomodulatory, and other pharmacological properties [45, 46]. Tripterygium wilfordii polyglycoside was found to inhibit Th17 cells differentiation by downregulating RORC and STAT3 expression, while IL-17 production upregulated Foxp3 and promoted Treg cells formation, further regulating Th17/Treg balance and inhibiting intestinal inflammation in colitic mice [47]. Baicalein is a flavonoid bioactive component derived from Scutellaria baicalensis, and its pharmacological effects, such as antibacterial, neuroprotective, and antitumor, have been demonstrated in a variety of disease models [48, 49]. A study found that baicalein could maintain intestinal immune homeostasis and reduce intestinal inflammatory damage in mice with colitis. Its intrinsic mechanism of action is to promote Treg cells differentiation by activating the aryl hydrocarbon receptor (AhR) while also lowering IL-6 levels and increasing TGF-β levels in colitic mice to prevent the onset of Th17 cells differentiation, thereby regulating the balance of Th17/Treg cells and alleviating colitic mouse symptoms [50]. There is evidence that the bioactive compound berberine, which is derived from the Chinese herb Coptis chinensis Franch., has a diversity of pharmacological properties, including anti-inflammatory, antioxidant, antiatherosclerotic, antibacterial, antidiabetic, and neuroprotective benefits [51, 52]. Berberine can reduce DAI, colon shortening, and colon tissue damage in IBD by regulating Treg/Th17 balance. It has been found that berberine inhibits the differentiation of naïve CD4+ T cells into Th17 cells by downregulating the expression of TGF-β. Simultaneous activation of AhR transcription factors, by upregulating cytochromeP4501A1 levels, increases Foxp3 expression, causes Treg cells differentiation, and comprehensively regulates Th17/Treg balance through these two pathways [53–55]. Alpinetin is a flavonoid isolated from Alpinia officinarum Hance, which has hepatoprotective, cardiovascular, antibacterial, antiviral, and neuroprotective effects and is widely used in medicine [56, 57]. Studies have confirmed that Alpinetin promotes Treg cells differentiation and restores Th17/Treg balance by activating AhR, promoting miR-302 expression, while downregulating DNA methyltransferase-1 expression, reducing Foxp3 promoter region methylation levels, promoting cAMP-response element binding protein binding to Foxp3 promoter region, and upregulating Foxp3 expression, further improving intestinal mucosal pathological outcomes in colitic mice, including alleviating surface epithelial damage and significantly reducing crypt number and inflammatory cell infiltration [58]. Abelmoschus manihot is a TCM having pharmacological properties, including immunomodulation, cardioprotection, antidiabetic nephropathy, anticonvulsant, and antidepressant [59]. According to a study, Abelmoschus manihot increases the expression of Foxp3 and specific cytokines in Treg cells while decreasing the expression of RoRγt and specific cytokines in Th17 cells, thereby balancing the expression of both to maintain intestinal immunological homeostasis [60]. The roots, barks, leaves, and flowers of Daphne odora Thunb. can all be used to extract Daphnetin. Modern pharmacological research has demonstrated that it has antioxidation, immunological modulation, and antitumor properties [61, 62]. Studies have shown that Daphnetin alleviates the symptoms of experimental colitis by alleviating colitis, improving colon injury, and reestablishing immune balance, and the intrinsic mechanism is that Daphnetin lessens the generation of Th17 cells while inhibiting the differentiation of Treg cells and restoring Th17/Treg balance [63]. Timosaponin AIII is one of the important active components extracted from Anemarrhena asphodeloides Bge., a TCM with a long history of medication, and most of its pharmacological effects are significant, while anticancer effects are potential [64, 65]. In a preliminary study by Lim et al. Timosaponin AIII could reduce NF-κB activation as well as the levels of IL-1β, tumor necrosis factor-alpha (TNF-α), and IL-6 and increase IL-10 levels, and in addition, it was found that cellular differentiation of Th17 in the colonic lamina propria was inhibited, while Treg cells were induced, indicating that Timosaponin AIII inhibited colonic shortening and myeloperoxidase activity in mice by inhibiting activation of nuclear factor kappa-B (NF-κB) and mitogen-activated protein kinase (MAPK) and restoring Th17/Treg balance for therapeutic purposes [66]. Poncirin is a flavonoid with extensive biological activities, including anticancer, antioxidant, antidiabetic, and other pharmacological effects [67]. A study showed that poncirin inhibited the differentiation of splenocytes into Th17 cells and the expression of IL-17 and Foxp3 in vitro and activated lipopolysaccharide- (LPS-) stimulated macrophages by inhibiting the binding of LPS to macrophage toll-like receptor 4. These increased the differentiation of splenocytes into Treg cells. Restoration of Th17/Treg imbalance through the above mechanisms suppresses NF-κB activation, thereby alleviating colitis [68]. Green tea can be used to extract the naturally occurring substance epigallocatechin-3-gallate. In human physiology and pathophysiology, it plays a complex role. According to pharmacological research, it has antioxidation, anticancer, and antifibrosis properties [69]. A study showed that epigallocatechin-3-gallate reduced the induced expression of RORγt by suppressing IL-16 and inhibiting the expression of STAT3 and hypoxia-inducible factor -1alpha(HIF-1α) protein, thereby reducing Th17 cells production. In mice with experimental colitis, IL-6 downregulation reduces the amount of Treg cells it suppresses and eventually restores the Treg/Th17 ratio, which lowers DAI and spleen index and lessens colonic tissue erosion [70]. Centella asiatica, the dried whole plant, a member of the Umbelliferae family, was founded in Shennong’s Classic of Materia Medica and is commonly used to treat various diseases of the digestive system, nervous system, and skin defense system. Madecassic acid is one of its main bioactive components, which has the effects of anticancer and anticancer [71]. Madecassic acid restores Th17/Treg balance by regulating the PPAR/AMPK/ACC1 pathway, resulting in anticolitis effects such as improved disease activity index, decreased colonic shortening, decreased myeloperoxidase activity, and decreased pathological damage in colitic mice colonic tissue [72]. One of the active ingredients in Atractylodes macrocephala Koidz. is costunolide, a naturally occurring sesquiterpene lactone, and pharmacological investigations have demonstrated that it has anticancer, anti-inflammatory, and antioxidant benefits [73, 74]. A study showed that oral administration of costunolide obviously improved DAI, rescued the reduction in colon length, and reduced proinflammatory cytokine levels in colitic mice. More in-depth mechanistic studies have shown that costunolide triggers the proteasomal degradation of the prolyl hydroxylase 2-triggered proline hydroxylation-ubiquitination-proteasome degradation of HIF-1α, inactivates the glycolytic process in Th17 cells, decreases the percentage of Th17 cells, and rebalances Th17/Treg in the colon and spleen [75]. Pharmacological studies have revealed that polydatin, one of the natural active ingredients isolated from the dried rhizomes of Polygonum cuspidatum Sieb., possesses asthmatic, antioxidant, and antitumor activities [76, 77]. As per studies, polydatin can successfully reduce the signs and symptoms of colitis in mice and protect and repair colonic mucosal tissues. This is done mostly by downregulating STAT3 signaling, inhibiting Th17 cell differentiation, thereby regulating the Th17/Treg balance [78]. A traditional Chinese herbal remedy called Lindera aggregata (Sims) Kosterm. has a diverse range of biological actions, including analgesic, antitumor, and antibacterial benefits. Studies have discovered that Lindera aggregata (Sims) Kosterm. can considerably reduce intestinal permeability and ameliorate colonic atrophy, both pathological alterations in colonic tissue that are common in UC model mice. The intrinsic mechanism of action is mainly to inhibit the production and secretion of IL-6, the transduction of the IL-6/STAT3 signaling pathway, and the polarization of Th17 in vivo, in order to adjust the balance of Th17 and Treg cells and ameliorate the symptoms and lesions of UC [79]. In clinical cases of inflammatory illnesses, cutaneous, mucosal, and other ailments, Indigo naturalis is frequently employed [80]. According to a study, Foxp3 and IL-10 expression were clearly up, RORγt and IL-17 expression were clearly down, and G protein-coupled receptor 41 (GPR41) and G protein-coupled receptor 43 (GPR43) protein expression were both noticeably higher in the colon of rats in the Qingdai group. Combined with the results of previous studies, it indicated that Indigo naturalis played a therapeutic role by affecting the GPR41/43 signaling pathway to regulate the downstream Th17/Treg balance [81] (Table 1).

4.2. Chinese Herbal Compound and Its Preparation Regulate Th17/Treg Cells Balance to Prevent and Treat IBD

Clinical trials and experimental studies have revealed that Th17/Treg imbalance has a correlation with the pathogenesis of IBD. Numerous studies of Chinese herbal compounds have also confirmed that intervention therapy with Chinese herbal compounds can regulate the imbalance status of Th17/Treg in IBD so as to achieve the effect of treating IBD. The main effects of these compounds are to clear heat and dampness, remove blood stasis and phlegm, and warm the intestine.

Gegen Qinlian Decoction (GQ), founded in the Treatise on Febrile Diseases, is a representative prescription for the treatment of clearing away heat and dampness to stop diarrhea and has been used in clinical settings for the long-term treatment of diarrhea and dysentery. Its ingredients include Pueraria lobata (Willd.), Coptis chinensis Franch., Scutellaria baicalensis, and Glycyrrhiza uralensis Fisch. [82]. Based on a study, administration of the GQ group significantly decreased the production of proinflammatory mediators, as well as the expression of inflammatory mediators like TGF-β1 and IL-17. It also inhibited the phosphorylation of JAK2 and STAT3, which in turn decreased STAT3’s ability to regulate transcription. Inhibiting IL-6/JAK2/STAT3 signaling to reinstate Treg and Th17 homeostasis in colon tissue helped Gegen Qinlian Decoction reduce the sickness overall [83]. Qingchang Wenzhong Formula (QCWZ) has the effects of clearing away heat and dampness and stopping bleeding. Coptis chinensis Franch., Ginger, Indigo naturalis, Sophora flavescens, Panax notoginseng, Ulmus charcoal, and other drugs are the main ingredients [84]. A study found that, after treatment with QCWZ, the expression of miR-675-5p, RORγt mRNA in the colon, and IL-17 in the serum of UC rats was increased, while the expression of VDR mRNA, Foxp3 mRNA, ZO-1, IL-10 in serum was significantly decreased compared with the blank group, indicating that QCWZ targets and regulates the VDR signaling pathway by decreasing the expression of miR-675-5p. Thus, Th17/Treg balance is regulated to achieve the therapeutic purpose of repairing intestinal mucosal barrier injury in UC patients [85]. The composition of Shaoyao decoction (SY) includes Paeonia lactiflora, Areca catechu L, Scutellaria baicalensis, Coptis chinensis, Angelica sinensis, Glycyrrhiza uralensis, and Aucklandia lappa Decne. It is often used in clinical practice to treat abdominal pain of damp-heat type and hematochezia [86]. A study found that SY could reduce IL-17 and IL-23 in serum, RORγt, and HIF-1α levels in the colon and increase IL-10 in the serum of UC rats, indicating that SY treatment of UC rats may be achieved by inhibiting HIF-1α to regulate the rebalance of Treg/Th17 [87]. Baitouweng Decoction (BTW) is a representative formula in Treatise on Febrile Diseases for the treatment of pus and blood under the stool caused by heat toxin flaming, which is widely used and has an effect on various enteritis. Its composition mainly includes four herbs: Pulsatilla chinensis, Coptis chinensis, Phellodendron amurense, and Cortex Fraxini [88]. BTW intervention decreased the expression of cytokines associated with Th17 cells differentiation (including IL-6, IL-1β, and TNF-α) and upregulated the expression of IL-10, a key indicator of Treg cells differentiation, thereby regulating the proportion of Th17 cells and Treg cells in mice and restoring Th17/Treg balance, in order to reduce DAI scores and colonic pathological damage in mice [89]. The ingredients of Jiedu Huayu Decoction (JDHY), a TCM remedy for blood circulation improvement and stasis removal, include Pulsatilla chinensis, Scutellaria barbata, Phellodendron amurense, Portulaca oleracea L., and Coptis chinensis. Dandan Li and colleagues discovered that JDHY could improve the clinical symptoms of active UC patients with dampness-heat accumulation by lowering IL-17 levels, increasing IL-10 and TGF-β levels, regulating the expression of RORγt and Foxp3 mRNA, promoting the recovery of Th17/Treg balance, and lowering the recurrence rate [90]. Compound sophorae decoction (CS) is a TCM formula composed of Sophora flavescens, Indigo naturalis, Glycyrrhiza uralensis, and Panax notoginseng powder. In the spleen and mesenteric lymph nodes of mice, a focused investigation discovered that CS could decrease the proportion of Th17 cells and raise the fraction of Treg cells. And the fundamental mechanism is to alter the Th17/Treg balance in mice in order to improve the relevant illness markers [91]. Rhubarb Peony Decoction (RP), from the classical ancient book of TCM Jin Gui Yao Lue, has the effect of purging heat and breaking and dissipating swelling. RP consists of Rhei Radix et Rhizoma, Moutan Cortex, and Persicae Semen. A study found that RP reduced the proportion of Th17 cells in colon tissue, increased the proportion of Treg cells, promoted the recovery of Th17/Treg balance, assisted mice to reduce pathological changes, and improved weight loss and tissue damage [92]. Bawei Xileisan (BWXL) is a traditional remedy for clearing away heat and toxic substances, relieving swelling, and relieving pain. In the past, diphtheria was primarily treated with it. In modern therapeutic practice, it can be utilized to heal ulcers and colonic inflammation [93]. In accordance with a study, BWXL enema improved dramatically the structure of the shortened colon and the damaged tissue. The mechanism is that the expression levels of Th17-related cytokines IL-17 A/F and IL-22 are significantly and dose-dependently reduced, resulting in restoration of the Th17/Treg balance [94]. The Yi-Yi-Fu-Zi-Bai-Jiang-San (YYFZBJ) prescription and syndrome take into account numerous elements, like cold, dampness, heat, blood stasis, yang insufficiency, and spleen deficiency. These factors have the impact of tonifying deficiency and purging excess, as well as controlling cold and heat [95]. Thus according to studies, YYFZBJ contains coix seed, aconite root, and Patrinia and has good efficacy and an antitumor function. Thus, according to studies, YYFZBJ contains coix seed, aconite root, and Patrinia and has good efficacy and an antitumor function. A study indicated that YYFZBJ reduced the expression of RORγt mRNA in colon tissue and the level of IL-17 in blood, increased the expression of Foxp3 mRNA and the level of IL-10, and further affected the numbers of Th17 and Treg cells to restore the Treg/Th17 balance. This balance has a therapeutic impact [96]. The effects of the Qingchang Huashi Recipe (QCHS) involve clearing heat and dampness, balancing qi and blood, and chilling blood to prevent dysentery. Astragalus membranaceus, Radix Paeoniae Alba, Pulsatillae Radix, Angelicae Dahuricae Radix, and Scutellariae Radix are among the herbs that make up this composition. The study found that QCHS could reduce the DAI score and improve pathological injury in mice, especially in the high dose group of QCHS, which had a significant therapeutic effect, and its mechanism may be through downregulating IDO1 expression, downregulating RORγt and related proinflammatory factors, and upregulating Foxp3 and related anti-inflammatory factors, so as to maintain the balance of Th17/Treg cytokine expression in order to achieve a therapeutic effect [97]. Huangqin Decoction (HQ) is frequently used in the treatment of IBD in clinical practice, and this study found that it could reduce the expression of Th17 cytokines IL-17, IL-6 protein and mRNA, and transcription factor RORγt protein while increasing the expression of Treg cytokines IL-10, TGF-β protein and mRNA, and the protein level of transcription factor Foxp3 in colitis rats. The results suggest that HQ can balance the imbalance of Th17/Treg through the regulation of cytokines and transcription factors, which may be the immune mechanism by which HQ exerts its effect and protects the intestinal mucosa [98]. Liancao Xieli Capsule (LCXL) is used as a TCM compound preparation in the treatment of IBD. A study found that LCXL can reduce the expression levels of p-STAT3 and RORγt proteins in the colon tissue of mice and increase the expression levels of p-STAT5 and Foxp3 proteins. The specific therapeutic effect demonstrated that body weight, colon length, and TGF-β content in mouse colon tissue were significantly increased, while DAI score, colon histopathological score, and IL-6 and IL-17A content were significantly reduced. The mechanism of regulating Treg/Th17 immune balance to improve intestinal inflammation in mice is mainly through inhibiting STAT3/RORγt and promoting the activation of the STAT5/Foxp3 signaling pathway [99]. Wei Chang An Pill (WCA) is a TCM preparation with the effects of aromatizing turbidity, regulating qi, relieving pain, strengthening the stomach, and guiding stagnation. It can repair the intestinal mucosal injury and relieve clinical symptoms. According to Tao Zhang’s study, different doses of WCA had distinct effects on the mouse colon tissues’ Treg/Th17 levels. To regulate both percentages and regain the proper balance between them, the therapeutic effect was obtained by upregulating Treg cell percentage and downregulating Th17 cell percentage [100]. Kaijieling (KJL) is a TCM formula preparation that can invigorate the spleen, clear away heat, and promote blood circulation. Ingredients in KJL include Atractylodes macrocephala, Paeonia lactiflora L., Hirudo, and Glycyrrhizauralensis. The results demonstrated that KJL modulated the associated cytokines and transcription factors to increase Treg cells and inhibit Th17 cells, alleviating the pathological damage to the colonic mucosa and lowering the histological score following treatment. In order to counteract the imbalance between Th17 and Treg cells, it also suppresses the STAT3 pathway. Another study further supported the hypothesis that KJL’s therapeutic effect may be due to a decrease in CD4+ IL-17A+ Th17 cells and an increase in CD4+ Foxp3+ Treg cells in peripheral blood, which in turn restores the body’s Treg/Th17 balance [101–103]. Xiaokui Recipe (XK) is composed of Pulsatilla chinensis, Punica granatum L., Lilii Bulbus, Galla chinensis, Tribulus terrestris, Coptis chinensis, and other TCMs. Huijian Zhang’s study showed that it could reduce the concentration of proinflammatory cytokines IL-17 and IL-6, increase the concentration of IL-10 and TGF-β, increase the expression of Foxp3, decrease the expression of RORγt, achieve the effect of promoting ulcer healing, indicating that XK could promote the differentiation and production of Treg cells in the colonic tissue of colitis rats, mediate the degree of immune tolerance, restrain the differentiation of Th17 cells to regulate Th17/Treg balance, maintain the immune balance in vivo, and reduce the intestinal inflammatory response, thus playing a therapeutic role [104]. Ulcerated enema is composed of Lonicera caprifolium and Lilii Bulbus. Intestinal fluid from ulceration enema (UE) may be therapeutic by regulating the Treg/Th17 immune balance in UC mice, specifically by increasing the number of Treg cells and upregulating IL-10 levels to reduce the number of Th17 cells. It has the effects of clearing away heat and dampness, protecting the membrane, and generating muscle [105] (Table 2).

5. Conclusions and Perspectives

Currently, a substantial body of research points to the dysregulated Th17/Treg balance as a key factor in the emergence of IBD. In patients with IBD, maintaining Th17/Treg balance is crucial for lowering intestinal mucosal inflammation, reliving clinical symptoms, and enhancing prognosis. We should investigate how TCM regulates the Th17/Treg balance in IBD because it has several targets and multiple regulatory mechanisms, is less toxic, and has reasonable R&D and usage costs. In order to find new complementary and alternative therapies from the core of IBD in combination with various disciplines, domestic and foreign scholars are actively conducting a large number of studies, collecting and screening the effective components and compounds of TCM, and doing so under the guiding advantages of TCM syndrome differentiation and treatment and overall concept. Although the paper explains the mechanism of action of TCM in regulating Th17/Treg balance to reduce the intestinal inflammatory response and repair intestinal mucosa in IBD patients, promoting intestinal immune response to protect intestinal mucosa, and improving clinical symptoms, it also provides a reference for the prevention and treatment of IBD by TCM. However, the pathogenesis of IBD, the composition of TCM ingredients, and TCM compounds are very complex, and the mechanism of action is not clear enough. The mechanism of action of TCM intervention in the treatment of IBD cannot be completely explained by regulating Th17/Treg balance, and it is necessary to use modern technologies such as systems biology and molecular informatics from multiple angles and interdisciplines for extensive and in-depth research and, at the same time, carry out some high-quality clinical randomized controlled experiments as soon as possible to break the limitations mainly based on basic research, which will not only improve the level of evidence but also help enrich the understanding of the role of TCM in the treatment of IBD and guide further achievement transformation and clinical medication reference.

Conflicts of Interest

These authors declare that they have no conflicts of interest.

Authors’ Contributions

Fengjiao Xie and Qin Xiong contributed equally to this work.

Acknowledgments

This work was funded by the National Key R&D Program of China (2018YFC1705403) and the Sichuan Medical Youth Innovative Scientific Research Project Plan (Q20001).

References

Q. Guan, “A comprehensive review and update on the pathogenesis of inflammatory bowel disease,” Journal of Immunology Research, vol. 2019, Article ID 7247238, 16 pages, 2019.
View at: Publisher Site | Google Scholar
S. S. Seyedian, F. Nokhostin, and M. D. Malamir, “A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease,” Journal of Medicine and Life, vol. 12, no. 2, pp. 113–122, 2019.
View at: Publisher Site | Google Scholar
T. Greuter and S. R. Vavricka, “Extraintestinal manifestations in inflammatory bowel disease - epidemiology, genetics, and pathogenesis,” Expert Review of Gastroenterology & Hepatology, vol. 13, no. 4, pp. 307–317, 2019.
View at: Publisher Site | Google Scholar
T. Sairenji, K. L. Collins, and D. V. Evans, “An update on inflammatory bowel disease,” Primary Care: Clinics in Office Practice, vol. 44, no. 4, pp. 673–692, 2017.
View at: Publisher Site | Google Scholar
T. Kucharzik, S. Koletzko, K. Kannengiesser, and A. Dignass, “Ulcerative colitis-diagnostic and therapeutic algorithms,” Deutsches Ärzteblatt International, vol. 117, no. 33-34, pp. 564–574, 2020.
View at: Publisher Site | Google Scholar
J. B. Yan, M. M. Luo, Z. Y. Chen, and B. H. He, “The function and role of the Th17/treg cell balance in inflammatory bowel disease,” Journal of Immunology Research, vol. 2020, Article ID 8813558, 8 pages, 2020.
View at: Publisher Site | Google Scholar
M. Noack and P. Miossec, “Th17 and regulatory T cell balance in autoimmune and inflammatory diseases,” Autoimmunity Reviews, vol. 13, no. 6, pp. 668–677, 2014.
View at: Publisher Site | Google Scholar
C. Z. Li and G. J. Chen, “Th17, Th17 cytokines and inflammatory bowel disease,” Immunological Journal, vol. 13, no. 6, pp. 668–677, 2014.
View at: Publisher Site | Google Scholar
G. R. Lee, “The balance of Th17 versus treg cells in autoimmunity,” International Journal of Molecular Sciences, vol. 19, no. 3, p. 730, 2018.
View at: Publisher Site | Google Scholar
S. Zhang, X. Gang, S. Yang et al., “The alterations in and the role of the Th17/treg balance in metabolic diseases,” Frontiers in Immunology, vol. 12, Article ID 678355, 2021.
View at: Publisher Site | Google Scholar
S. Cerboni, U. Gehrmann, S. Preite, and S. Mitra, “Cytokine-regulated Th17 plasticity in human health and diseases,” Immunology, vol. 163, no. 1, pp. 3–18, 2021.
View at: Publisher Site | Google Scholar
M. B. Torchinsky and J. M. Blander, “T helper 17 cells: discovery, function, and physiological trigger,” Cellular and Molecular Life Sciences, vol. 67, no. 9, pp. 1407–1421, 2010.
View at: Publisher Site | Google Scholar
P. Fasching, M. Stradner, W. Graninger, C. Dejaco, and J. Fessler, “Therapeutic potential of targeting the Th17/treg Axis in autoimmune disorders,” Molecules, vol. 22, no. 1, p. 134, 2017.
View at: Publisher Site | Google Scholar
S. H. Li and Q. F. Wu, “The progress of the roles of gut flora in Th17/Treg axis balance and inflammatory bowel diseases,” Immunological Journal, vol. 35, no. 08, pp. 722–726, 2019.
View at: Publisher Site | Google Scholar
F. A. R. Silva, B. L. Rodrigues, M. d. L. S. Ayrizono, and R. F. Leal, “The immunological basis of inflammatory bowel disease,” Gastroenterology Research and Practice, vol. 2016, pp. 1–11, 2016.
View at: Publisher Site | Google Scholar
B. Zeng, S. Shi, G. Ashworth, C. Dong, J. Liu, and F. Xing, “ILC3 function as a double-edged sword in inflammatory bowel diseases,” Cell Death & Disease, vol. 10, no. 4, p. 315, 2019.
View at: Publisher Site | Google Scholar
W. Jiang, J. Su, X. Zhang et al., “Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease,” Inflammation Research, vol. 63, no. 11, pp. 943–950, 2014.
View at: Publisher Site | Google Scholar
G. Latella and A. Viscido, “Controversial contribution of Th17/IL-17 toward the immune response in intestinal fibrosis,” Digestive Diseases and Sciences, vol. 65, no. 5, pp. 1299–1306, 2020.
View at: Publisher Site | Google Scholar
A. R. Moschen, H. Tilg, and T. Raine, “IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting,” Nature Reviews Gastroenterology & Hepatology, vol. 16, no. 3, pp. 185–196, 2019.
View at: Publisher Site | Google Scholar
L. A. Lucaciu, M. Ilieș, Ș. C. Vesa et al., “Serum interleukin (IL)-23 and IL-17 profile in inflammatory bowel disease (IBD) patients could differentiate between severe and non-severe disease,” Journal of Personalized Medicine, vol. 11, no. 11, p. 1130, 2021.
View at: Publisher Site | Google Scholar
B. Zhang, Y. Liu, X. Lan et al., “Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice,” Journal of Translational Medicine, vol. 16, no. 1, p. 71, 2018.
View at: Publisher Site | Google Scholar
M. Viladomiu, M. L. Metz, S. F. Lima et al., “Adherent-invasive E. coli metabolism of propanediol in Crohn's disease regulates phagocytes to drive intestinal inflammation,” Cell Host & Microbe, vol. 29, no. 4, pp. 607–619, 2021.
View at: Publisher Site | Google Scholar
X. L. Huang, X. Zhang, X. Y. Fei et al., “Faecalibacterium prausnitzii supernatant ameliorates dextran sulfate sodium induced colitis by regulating Th17 cell differentiation,” World Journal of Gastroenterology, vol. 22, no. 22, pp. 5201–5210, 2016.
View at: Publisher Site | Google Scholar
J. N. Clough, O. S. Omer, S. Tasker, G. M. Lord, and P. M. Irving, “Regulatory T-cell therapy in Crohn's disease: challenges and advances,” Gut, vol. 69, no. 5, pp. 942–952, 2020.
View at: Publisher Site | Google Scholar
T. V. Velikova, L. Miteva, N. Stanilov, Z. Spassova, and S. A. Stanilova, “Interleukin-6 compared to the other Th17/Treg related cytokines in inflammatory bowel disease and colorectal cancer,” World Journal of Gastroenterology, vol. 26, no. 16, pp. 1912–1925, 2020.
View at: Publisher Site | Google Scholar
W. Zhang, X. Liu, Y. Zhu et al., “Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease,” European Journal of Immunology, vol. 51, no. 9, pp. 2137–2150, 2021.
View at: Publisher Site | Google Scholar
S. Negi, S. Saini, N. Tandel, K. Sahu, R. P. N. Mishra, and R. K. Tyagi, “Translating treg therapy for inflammatory bowel disease in humanized mice,” Cells, vol. 10, no. 8, p. 1847, 2021.
View at: Publisher Site | Google Scholar
Y. Fan, Y. Fan, K. Liu et al., “Edible bird’s nest ameliorates dextran sulfate sodium-induced ulcerative colitis in C57bl/6J mice by restoring the Th17/treg cell balance,” Frontiers in Pharmacology, vol. 12, Article ID 632602, 2021.
View at: Publisher Site | Google Scholar
Y. Chang, L. Zhai, J. Peng, H. Wu, Z. Bian, and H. Xiao, “Phytochemicals as regulators of Th17/Treg balance in inflammatory bowel diseases,” Biomedicine & Pharmacotherapy, vol. 141, Article ID 111931, 2021.
View at: Publisher Site | Google Scholar
J. Karczewski, M. Mazur, A. Rychlewska-Hanczewska, and Z. Adamski, “[Role of Th17 lymphocytes in pathogenesis of colorectal cancer],” Postepy Higieny I Medycyny Doswladczalnej, vol. 68, pp. 42–47, 2014.
View at: Publisher Site | Google Scholar
S. Hang, D. Paik, L. Yao et al., “Bile acid metabolites control TH17 and Treg cell differentiation,” Nature, vol. 576, no. 7785, pp. 143–148, 2019.
View at: Publisher Site | Google Scholar
F. Zhu, H. Li, Y. Liu et al., “miR-155 antagomir protect against DSS-induced colitis in mice through regulating Th17/Treg cell balance by Jarid2/Wnt/β-catenin,” Biomedicine & Pharmacotherapy, vol. 126, Article ID 109909, 2020.
View at: Publisher Site | Google Scholar
L. Zhang and W. Wei, “Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony,” Pharmacology & Therapeutics, vol. 207, Article ID 107452, 2020.
View at: Publisher Site | Google Scholar
H. Jiang, J. Li, L. Wang et al., “Total glucosides of paeony: a review of its phytochemistry, role in autoimmune diseases, and mechanisms of action,” Journal of Ethnopharmacology, vol. 258, Article ID 112913, 2020.
View at: Publisher Site | Google Scholar
Y. Xiang, Q. Zhang, S. Wei, C. Huang, Z. Li, and Y. Gao, “Paeoniflorin: a monoterpene glycoside from plants of Paeoniaceae family with diverse anticancer activities,” Journal of Pharmacy and Pharmacology, vol. 72, no. 4, pp. 483–495, 2020.
View at: Publisher Site | Google Scholar
K. Zheng, J. Jia, S. Yan, H. Shen, P. Zhu, and J. Yu, “Paeoniflorin ameliorates ulcerative colitis by modulating the dendritic cell-mediated TH17/Treg balance,” Inflammopharmacology, vol. 28, no. 6, pp. 1705–1716, 2020.
View at: Publisher Site | Google Scholar
Q. Li, Q. Shan, X. Sang, R. Zhu, X. Chen, and G. Cao, “Total glycosides of peony protects against inflammatory bowel disease by regulating IL-23/IL-17 Axis and Th17/treg balance,” The American Journal of Chinese Medicine, vol. 47, no. 01, pp. 177–201, 2019.
View at: Publisher Site | Google Scholar
R. R. Kotha and D. L. Luthria, “Curcumin: biological, pharmaceutical, nutraceutical, and analytical aspects,” Molecules, vol. 24, no. 16, p. 2930, 2019.
View at: Publisher Site | Google Scholar
T. Tsuda, “Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives,” Food & Function, vol. 9, no. 2, pp. 705–714, 2018.
View at: Publisher Site | Google Scholar
C. Wei, J. Y. Wang, F. Xiong et al., “Curcumin ameliorates DSSinduced colitis in mice by regulating the Treg/Th17 signaling pathway,” Molecular Medicine Reports, vol. 23, no. 1, 2020.
View at: Publisher Site | Google Scholar
A. A. Oyagbemi, A. B. Saba, and O. I. Azeez, “Molecular targets of [6]-gingerol: its potential roles in cancer chemoprevention,” BioFactors, vol. 36, no. 3, pp. 169–178, 2010.
View at: Publisher Site | Google Scholar
N. F. N. Mohd Sahardi and S. Makpol, “Ginger (zingiber officinale Roscoe) in the prevention of ageing and degenerative diseases: review of current evidence,” Evidence-based Complementary and Alternative Medicine, vol. 2019, pp. 1–13, 2019.
View at: Publisher Site | Google Scholar
Y. Sheng, T. Wu, Y. Dai, K. Ji, Y. Zhong, and Y. Xue, “The effect of 6-gingerol on inflammatory response and Th17/Treg balance in DSS-induced ulcerative colitis mice,” Annals of Translational Medicine, vol. 8, no. 7, p. 442, 2020.
View at: Publisher Site | Google Scholar
Y. Y. Sheng, The Clinical Study of Shengjiang Xiexin Decoction in Cold-Heat Complex Syndrimes in the Treatment of Ulcerative Colitis and the Mechanism of 6-gingerol Intervention, Nanjing University of Chinese Medicine, Nanjing, China, 2021.
Q. Li, Y. Huang, P. Liu, H. Yuan, and J. Zhao, “Effect of Tripterygium wilfordii polyglycoside tablets on serum inflammatory factors and T cells in patients with chronic nephritis,” American Journal of Translational Research, vol. 13, no. 7, pp. 8385–8390, 2021.
View at: Google Scholar
Y. Guo, N. Guo, J. Wang, R. Wang, and L. Tang, “Retrospective analysis of Tripterygium wilfordii polyglycoside combined with angiotensin receptor blockers for the treatment of primary membranous nephropathy with sub-nephrotic proteinuria,” Renal Failure, vol. 43, no. 1, pp. 729–736, 2021.
View at: Publisher Site | Google Scholar
C. Zhang, J. Ju, X. Wu et al., “Tripterygium wilfordii polyglycoside ameliorated TNBS-induced colitis in rats via regulating Th17/treg balance in intestinal mucosa,” Journal of Inflammation Research, vol. 14, pp. 1243–1255, 2021.
View at: Publisher Site | Google Scholar
B. Dinda, S. Dinda, S. DasSharma, R. Banik, A. Chakraborty, and M. Dinda, “Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders,” European Journal of Medicinal Chemistry, vol. 131, pp. 68–80, 2017.
View at: Publisher Site | Google Scholar
K. Sowndhararajan, P. Deepa, M. Kim, S. J. Park, and S. Kim, “Baicalein as a potent neuroprotective agent: a review,” Biomedicine & Pharmacotherapy, vol. 95, pp. 1021–1032, 2017.
View at: Publisher Site | Google Scholar
C. Liu, Y. Li, Y. Chen et al., “Baicalein restores the balance of Th17/treg cells via aryl hydrocarbon receptor to attenuate colitis,” Mediators of Inflammation, vol. 2020, pp. 1–19, 2020.
View at: Publisher Site | Google Scholar
D. Song, J. Hao, and D. Fan, “Biological properties and clinical applications of berberine,” Frontiers of Medicine, vol. 14, no. 5, pp. 564–582, 2020.
View at: Publisher Site | Google Scholar
A. Och, R. Podgorski, and R. Nowak, “Biological activity of berberine-A summary update,” Toxins, vol. 12, no. 11, p. 713, 2020.
View at: Publisher Site | Google Scholar
S. M. Ehteshamfar, M. Akhbari, J. T. Afshari et al., “Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation,” Journal of Cellular and Molecular Medicine, vol. 24, no. 23, pp. 13573–13588, 2020.
View at: Publisher Site | Google Scholar
H. Cui, Y. Cai, L. Wang et al., “Berberine regulates treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon,” Frontiers in Pharmacology, vol. 9, p. 571, 2018.
View at: Publisher Site | Google Scholar
Y. H. Li, H. T. Xiao, D. D. Hu et al., “Berberine ameliorates chronic relapsing dextran sulfate sodium-induced colitis in C57BL/6 mice by suppressing Th17 responses,” Pharmacological Research, vol. 110, pp. 227–239, 2016.
View at: Publisher Site | Google Scholar
G. Zhao, Y. Tong, F. Luan et al., “Alpinetin: a review of its pharmacology and pharmacokinetics,” Frontiers in Pharmacology, vol. 13, Article ID 814370, 2022.
View at: Publisher Site | Google Scholar
Z. Yu, B. Yue, L. Ding et al., “Activation of PXR by Alpinetin contributes to abrogate chemically induced inflammatory bowel disease,” Frontiers in Pharmacology, vol. 11, p. 474, 2020.
View at: Publisher Site | Google Scholar
Q. Lv, C. Shi, S. Qiao et al., “Alpinetin exerts anti-colitis efficacy by activating AhR, regulating miR-302/DNMT-1/CREB signals, and therefore promoting Treg differentiation,” Cell Death & Disease, vol. 9, no. 9, p. 890, 2018.
View at: Publisher Site | Google Scholar
F. Luan, Q. Wu, Y. Yang et al., “Traditional uses, chemical constituents, biological properties, clinical settings, and toxicities of Abelmoschus manihot L.: a comprehensive review,” Frontiers in Pharmacology, vol. 11, p. 1068, 2020.
View at: Publisher Site | Google Scholar
W. Zhang, C. Cheng, Q. Han et al., “Flos Abelmoschus manihot extract attenuates DSS-induced colitis by regulating gut microbiota and Th17/Treg balance,” Biomedicine & Pharmacotherapy, vol. 117, Article ID 109162, 2019.
View at: Publisher Site | Google Scholar
E. H. M. Hassanein, A. M. Sayed, O. E. Hussein, and A. M. Mahmoud, “Coumarins as modulators of the keap1/nrf2/ARE signaling pathway,” Oxidative Medicine and Cellular Longevity, vol. 2020, pp. 1–25, 2020.
View at: Publisher Site | Google Scholar
S. Han, L. Z. Li, and S. J. Song, “Daphne giraldii Nitsche (Thymelaeaceae): phytochemistry, pharmacology and medicinal uses,” Phytochemistry, vol. 171, Article ID 112231, 2020.
View at: Publisher Site | Google Scholar
J. Ji, X. Ge, Y. Chen et al., “Daphnetin ameliorates experimental colitis by modulating microbiota composition and Treg/Th17 balance,” The FASEB Journal, vol. 33, no. 8, pp. 9308–9322, 2019.
View at: Publisher Site | Google Scholar
Y. Lin, W. R. Zhao, W. T. Shi et al., “Pharmacological activity, pharmacokinetics, and toxicity of Timosaponin AIII, a natural product isolated from Anemarrhena asphodeloides bunge: a review,” Frontiers in Pharmacology, vol. 11, p. 764, 2020.
View at: Publisher Site | Google Scholar
F. R. S. Passos, H. G. Araujo-Filho, B. S. Monteiro et al., “Anti-inflammatory and modulatory effects of steroidal saponins and sapogenins on cytokines: a review of pre-clinical research,” Phytomedicine, vol. 96, Article ID 153842, 2022.
View at: Publisher Site | Google Scholar
S. M. Lim, J. J. Jeong, G. D. Kang, K. A. Kim, H. S. Choi, and D. H. Kim, “Timosaponin AIII and its metabolite sarsasapogenin ameliorate colitis in mice by inhibiting NF-κB and MAPK activation and restoring Th17/Treg cell balance,” International Immunopharmacology, vol. 25, no. 2, pp. 493–503, 2015.
View at: Publisher Site | Google Scholar
F. Alam, K. Mohammadin, Z. Shafique, S. T. Amjad, and M. Asad, “Citrus flavonoids as potential therapeutic agents: a review,” Phytotherapy Research, vol. 36, no. 4, pp. 1417–1441, 2022.
View at: Publisher Site | Google Scholar
G. D. Kang and D. H. Kim, “Poncirin and its metabolite ponciretin attenuate colitis in mice by inhibiting LPS binding on TLR4 of macrophages and correcting Th17/Treg imbalance,” Journal of Ethnopharmacology, vol. 189, pp. 175–185, 2016.
View at: Publisher Site | Google Scholar
C. Chu, J. Deng, Y. Man, and Y. Qu, “Green tea extracts epigallocatechin-3-gallate for different treatments,” BioMed Research International, vol. 2017, pp. 1–9, 2017.
View at: Publisher Site | Google Scholar
Z. Xu, C. Wei, R. U. Zhang, J. Yao, D. Zhang, and L. Wang, “Epigallocatechin-3-gallate-induced inhibition of interleukin-6 release and adjustment of the regulatory T/T helper 17 cell balance in the treatment of colitis in mice,” Experimental and Therapeutic Medicine, vol. 10, no. 6, pp. 2231–2238, 2015.
View at: Publisher Site | Google Scholar
F. A. Torbati, M. Ramezani, R. Dehghan et al., “Ethnobotany, phytochemistry and pharmacological features of Centella asiatica: a comprehensive review,” Advances in Experimental Medicine & Biology, vol. 1308, pp. 451–499, 2021.
View at: Publisher Site | Google Scholar
X. Xu, Y. Wang, Z. Wei et al., “Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway,” Cell Death & Disease, vol. 8, no. 3, p. e2723, 2017.
View at: Publisher Site | Google Scholar
Q. Li, Z. Wang, Y. Xie, and H. Hu, “Antitumor activity and mechanism of costunolide and dehydrocostus lactone: two natural sesquiterpene lactones from the Asteraceae family,” Biomedicine & Pharmacotherapy, vol. 125, Article ID 109955, 2020.
View at: Publisher Site | Google Scholar
X. Lin, Z. Peng, and C. Su, “Potential anti-cancer activities and mechanisms of costunolide and dehydrocostuslactone,” International Journal of Molecular Sciences, vol. 16, no. 12, Article ID 10888, 2015.
View at: Publisher Site | Google Scholar
Q. Lv, Y. Xing, D. Dong et al., “Costunolide ameliorates colitis via specific inhibition of HIF1α/glycolysis-mediated Th17 differentiation,” International Immunopharmacology, vol. 97, Article ID 107688, 2021.
View at: Publisher Site | Google Scholar
P. Ye, H. Wu, Y. Jiang et al., “Old dog, new tricks: polydatin as a multitarget agent for current diseases,” Phytotherapy Research, vol. 36, no. 1, pp. 214–230, 2022.
View at: Publisher Site | Google Scholar
Q. H. Du, C. Peng, and H. Zhang, “Polydatin: a review of pharmacology and pharmacokinetics,” Pharmaceutical Biology, vol. 51, no. 11, pp. 1347–1354, 2013.
View at: Publisher Site | Google Scholar
Y. J. Liu, Effect of Polydatin on Murine Inflammatory Bowel Disease and its Possible Mechanism, Fujian University of traditional Chinese Medicine, Fuzhou, China, 2021.
H. Lai, Z. Yang, Z. Lou et al., “Root extract of Lindera aggregata (sims) Kosterm. Modulates the Th17/treg balance to attenuate DSS-induced colitis in mice by IL-6/STAT3 signaling pathway,” Frontiers in Pharmacology, vol. 12, Article ID 615506, 2021.
View at: Publisher Site | Google Scholar
Q. Sun, J. Leng, L. Tang, L. Wang, and C. Fu, “A comprehensive review of the chemistry, pharmacokinetics, pharmacology, clinical applications, adverse events, and quality control of indigo naturalis,” Frontiers in Pharmacology, vol. 12, Article ID 664022, 2021.
View at: Publisher Site | Google Scholar
Z. M. Sun, J. X. Li, Q. Q. Lu et al., “Study on the mechanism of indigo naturalis regulating the immune balance of treg/Th17 by affecting GPR41/43 signaling pathway in DSS-induced ulcerative colitis of rats,” Journal of Emrgency In Traditional Chinese Medicine, vol. 30, no. 04, pp. 604–607, 2021.
View at: Google Scholar
J. Z. Lu, D. Ye, and B. L. Ma, “Constituents, pharmacokinetics, and pharmacology of gegen-qinlian decoction,” Frontiers in Pharmacology, vol. 12, Article ID 668418, 2021.
View at: Publisher Site | Google Scholar
Y. Zhao, H. Luan, H. Jiang et al., “Gegen Qinlian decoction relieved DSS-induced ulcerative colitis in mice by modulating Th17/Treg cell homeostasis via suppressing IL-6/JAK2/STAT3 signaling,” Phytomedicine, vol. 84, Article ID 153519, 2021.
View at: Publisher Site | Google Scholar
Z. M. Sun, X. W. Chen, L. M. Hu et al., “Study on Qingchang Wenzhong Decoction in treatment of remission ulcerative colitis,” Journal of Integrated Traditional and Western Medicine on Digestion, vol. 29, no. 09, pp. 619–623, 2021.
View at: Google Scholar
Z. M. Sun, P. H. Ding, W. T. Wang et al., “Effect of Qingchang wenzhong decoction on miR-675-5p/VDR signaling pathway in rats with DSS-induced ulcerative colitis,” Journal of Emrgency In Traditional Chinese Medicine, vol. 28, no. 01, pp. 94–108, 2019.
View at: Google Scholar
B. Zou and H. Cao, “Meta-analysis ofEffect of retaintion enema wjith modified Shaoyao decoctionor combined with western medicine in treatment of ulcerative colitis,” Journal of Practical Traditional Chinese Internal Medicine, vol. 35, no. 08, pp. 32–34, 2021.
View at: Publisher Site | Google Scholar
D. S. Wu, H. Cao, Y. Zhang, Z. LI, and Y. LU, “Shaoyaotang treats ulcerative colitis by inhibiting HIF-1α and regulating Th17/treg balance,” Chinese Journal of Experimental Traditional Medical Formulae, vol. 27, no. 24, pp. 9–15, 2021.
View at: Publisher Site | Google Scholar
L. Lu, “Clinical study on the methods of clearing heat and eliminating dampness combined with mesalazine in the treatment of ulcerative colitis,” Research of intergrated Traditional Chinese and Western Medicine, vol. 13, no. 06, pp. 373–376, 2021.
View at: Google Scholar
Z. Miao, L. Chen, H. Feng et al., “Baitouweng decoction ameliorates ulcerative colitis in mice partially attributed to regulating Th17/treg balance and restoring intestinal epithelial barrier,” Frontiers in Pharmacology, vol. 11, Article ID 531117, 2020.
View at: Publisher Site | Google Scholar
D. D. Li, X. X. Yuan, L. Yang, and Nangang Branch of Heilongjiang Academy of Traditional Chinese Medicine, “Effects of Jiedu Huayu decoction on Th17/treg cells and its cytokines on patients with active ulcerative colitis,” Journal of Emrgency In Traditional Chinese Medicine, vol. 11, Article ID 531117, 2020.
View at: Google Scholar
M. Xu, X. Y. Duan, Q. Y. Chen et al., “Effect of compound sophorae decoction on dextran sodium sulfate (DSS)-induced colitis in mice by regulating Th17/Treg cell balance,” Biomedicine & Pharmacotherapy, vol. 109, pp. 2396–2408, 2019.
View at: Publisher Site | Google Scholar
S. Luo, R. Wen, Q. Wang et al., “Rhubarb Peony Decoction ameliorates ulcerative colitis in mice by regulating gut microbiota to restoring Th17/Treg balance,” Journal of Ethnopharmacology, vol. 231, pp. 39–49, 2019.
View at: Publisher Site | Google Scholar
L. Huang, T. G. Liu, C. Bai et al., “Textual research on xilei powder,” China Journal of Chinese Materia Medica, vol. 45, no. 17, pp. 4262–4266, 2020.
View at: Publisher Site | Google Scholar
J. Wen, B. Teng, P. Yang et al., “The potential mechanism of Bawei Xileisan in the treatment of dextran sulfate sodium-induced ulcerative colitis in mice,” Journal of Ethnopharmacology, vol. 188, pp. 31–38, 2016.
View at: Publisher Site | Google Scholar
B. G. Zhang and Q. F. Liu, “Research progress of Coix monkshood Patrinia powder (soup) and its modified clinical application,” Chinese Traditional Patent Medicine, vol. 37, no. 09, pp. 2026–2028, 2015.
View at: Google Scholar
S. X. Zhang and R. J. Shi, “Effect of yiyi fuzi baijiang powder on treg/Th17 in rats with TNBS-induced colitis,” World Chinese Journal of Digestology, vol. 22, no. 11, pp. 1542–1546, 2014.
View at: Publisher Site | Google Scholar
E. Zhou, L. Zhu, and H. Shen, “Qingchang Huashi formula treating UC by influencing Ido1 in regulating Th17/treg balance,” Information on Traditional Chinese Medicine, vol. 39, no. 02, pp. 7–13, 2022.
View at: Publisher Site | Google Scholar
Y. Zou, Effect of Huangqin-Tang on the Balance of Th1/Th2 and Th17/Treg Cells in TNBS-Induced Colitis in Rats, Southern Medical University, Guangzhou, China, 2012.
J. Y. Zhan, X. X. Yuan, Y. L. Zhang, C. F. Liu, and B. Y. Wang, “Mechanism of Liancao Xieli capsule in the treatment of ulcerative colitis through the differentiation of Th17 and Treg cells,” Journal of Hainan Medical University, vol. 27, no. 23, pp. 1768–1774, 2021.
View at: Publisher Site | Google Scholar
T. Zhang, X. L. Su, X. Y. Mao et al., “Effects of weichang’an pill on treg/Th17 immune balance in ulcerative colitis model mice,” Journal of Traditional Chinese Medicine, vol. 61, no. 22, pp. 1983–1989, 2020.
View at: Publisher Site | Google Scholar
Y. Long, S. Li, J. Qin et al., “Kuijieling regulates the differentiation of Treg and Th17 cells to ameliorate experimental colitis in rats,” Biomedicine & Pharmacotherapy, vol. 105, pp. 781–788, 2018.
View at: Publisher Site | Google Scholar
Y. Long, Y. He, F. Jie et al., “Kuijieling-containing serum regulates Th17 and treg cell differentiation by inhibiting STAT3 signaling in vitro,” Evidence-based Complementary and Alternative Medicine, vol. 2019, pp. 1–9, 2019.
View at: Publisher Site | Google Scholar
Z. F. Liu, Z. Guo, Y. W. Li et al., “Effects of kuijieling on balance of peripheral blood treg/Th17 in experimental ulcerative colitis rats,” Traditional Chinese Drug Research & Clinical Pharmacology, vol. 26, no. 01, pp. 1–5, 2015.
View at: Google Scholar
H. J. Zhang, P. F. Zhou, S. J. Liu, D. W. Liu, and X. C. Zhang, “Mechanism of Xiaokui enema formula in the treatment of rat ulcerative colitis,” Journal of Beijing University of Traditional Chinese Medicine, vol. 42, no. 07, pp. 577–583, 2019.
View at: Google Scholar
Y. Ding, “Effect of kuijie guanchang prescription regulation treg/Th17Balance on intestinal inflammatory response in DSS mices,” NanjinUniversity of Traditional Chinese Medicine, 2019.
View at: Google Scholar

Copyright

Copyright © 2022 Fengjiao Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PDF Download Citation

Download other formats

Order printed copies

Views

665

Downloads

578

Citations